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Abstract
Pregnancy-related acute kidney injury (AKI) may be associated with significant morbidity
and mortality in young and often otherwise healthy women. We conducted a retrospective
cohort study of all consecutive pregnancies between 1997 and 2011 in Ontario and describe
the incidence, characteristics, and outcomes of AKI treated with dialysis (AKI-D) during
pregnancy or within 12 weeks postpartum. Of 1,918,789 pregnancies, 188 were complicated
by AKI-D (incidence proportion: 1 per 10,000, 95% confidence interval 0.8 to 1.1). Eight
women died (4.3% versus 0.01% in the general population) and seven (3.9%) survivors
remained dialysis-dependent four months after delivery. The presence of AKI-D was
associated with several maternal complications as well as low birth weight, small for
gestational age, and preterm birth among infants, although there were no stillbirths and fewer
than five neonatal deaths in affected pregnancies. In conclusion, AKI-D in pregnancy is rare.
Most affected women and their babies have good short-term outcomes.
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Glossary of Terms
Acidosis – increased acidity in the blood or body tissue
Acute tubular necrosis – kidney failure caused by damage to the tubules (in the kidney), often
caused by decreased blood flow
Alkalosis – increased alkalinity in the blood or body tissue
Aminoaciduria – excessive excretion of amino acids in the urine
Calyces – a system of ducts in the kidneys that carry urine
Cardiogenic shock – shock resulting from heart failure
Chorioamnionitis – inflammation of the fetal membranes, caused by infection
Creatinine – a muscle breakdown product that is filtered by the kidneys and excreted in the
urine
Edema – swelling caused by excess fluid in body tissues
Endomyometritis – inflammation of the endometrium, caused by an infection
Glomerulonephritis – inflammation of the glomerulus (in the kidney), often caused by an
immune response
Glomerulus – a cluster of small blood vessels involved in filtering waste products from the
blood
Glucosuria – excessive excretion of glucose in the urine
Gravid – pregnant
Hydronephrosis – kidney swelling due to urine outflow obstruction
Hyperfiltration – increased glomerular filtration rate
xii

Hyperkalemia – abnormally high level of potassium in the blood
Hypokalemia – abnormally low level of potassium in the blood
Hyponatremia – abnormally low level of sodium in the blood
Interstitial nephritis – inflammation of the spaces between the tubules (in the kidney), often
caused by an immune response
Inulin – a small, inert polysaccharide molecule that is used to measure kidney function
Ischemia – inadequate blood supply to an organ
Lupus nephritis – inflammation of the kidney, caused by systemic lupus erythematosus
Microangiopathic hemolytic anemia – loss of red blood cells through destruction from
passage through small, partially occluded, blood vessels
Nulliparous – no history of pregnancy resulting in childbirth
Polyhydramnios – excessive amniotic fluid in the amniotic sac
Preeclampsia – a condition characterized by high blood pressure and proteinuria in
pregnancy
Proteinuria – excessive excretion of proteins in the urine
Pyelonephritis – inflammation of the kidney, caused by infection
Renal cortical necrosis – a rare cause of kidney failure caused by decreased blood flow to the
kidney
Thrombocytopenia – abnormally low platelets in the blood
Uremia – a clinical syndrome produced by accumulation of toxins due to kidney failure
Vasoconstriction – constriction of blood vessels, which increases blood pressure
Vasodilation – dilatation of blood vessels, which decreases blood pressure
xiii
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Chapter 1

1

Introduction

1.1 Background and Overview
Pregnancy-related acute kidney injury (AKI) is associated with significant morbidity and
mortality in young and often otherwise healthy women.1,2 Since the 1960s, the incidence
of pregnancy-related AKI in developed countries has declined from 1 in 3,000 to
approximately 1 in 18,000.1 This trend has been closely linked to improved obstetrical
care and dramatic reductions in first-trimester AKI attributable to septic abortions.3
However, these trends are less relevant in contemporary populations. The changing risk
profile of pregnant North American women includes lower parity, older age, higher body
mass index, and greater comorbidities such as hypertension, diabetes mellitus, and
chronic kidney disease, as well as increased use of reproductive technologies resulting in
multifetal gestations.4–8 These changes may have a unique impact on the incidence and
outcomes of pregnancy-related AKI.
We reviewed the literature to better understand kidney function and AKI in pregnancy,
and to identify knowledge gaps for further study. We conducted the present study to
determine the incidence, characteristics, and outcomes of the most severe cases of AKI in
pregnancy, namely those treated with dialysis, in a contemporary cohort of 1.9 million
pregnancies in Ontario, Canada.
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Chapter 2

2

Literature Review

2.1 The Normal Kidney
2.1.1 Brief Overview of Kidney Function
The kidney is a vital organ and has several key functions. These include (1) excretion of
waste products of metabolism such as urea, creatinine, and uric acid, (2) regulation of
fluid and electrolytes, including sodium, potassium, and hydrogen, and (3) secretion of
hormones that regulate local and systemic hemodynamics, red cell production, and
mineral metabolism.9

2.1.2 Measurement of Kidney Function
The glomerular filtration rate is used to assess the level of kidney function and is equal to
the sum of the filtration rates in all functioning nephrons (filtration units in the kidney).9
This can be measured by timing urinary clearance of inulin, a physiologically inert
substance that is freely filtered by the glomerulus without being secreted, reabsorbed,
synthesized, or metabolized by the kidney.10 However, this method is complex and even
though less cumbersome methods for measuring clearance are available (using alternative
filtration markers and plasma clearance), it has largely been replaced by estimations of
glomerular filtration rate using creatinine clearance or estimation equations such as the
Cockcroft-Gault equation,11 the Modification of Diet in Renal Disease (MDRD) study
equations,12 and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
equation.13 All of these equations are dependent on serum creatinine concentration, with
higher serum creatinine concentrations translating to lower estimated glomerular
filtration rates.
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2.2 The Kidney in Pregnancy
2.2.1 Brief Overview of Physiologic Changes in Pregnancy
Several anatomic and physiologic changes occur in the kidney and urinary tract to
accommodate pregnancy. Understanding these changes is essential to accurate
recognition and management of AKI during pregnancy and the postpartum period.
Both kidney length and volume change during pregnancy. Kidney volume increases by
up to 30% as a result of increases in vascular and interstitial spaces, and kidney length
increases by 1-1.5 cm with dilatation of the urinary collecting system.14 Dilatation of the
renal pelvises, calyceal systems, and ureters occurs as early as 6 weeks gestation and is
typically more pronounced on the right side.15 Hydronephrosis occurs in up to 80% of
women.15 Urinary stasis in this setting can also predispose women to ascending urinary
tract infections such as pyelonephritis.15
Several hemodynamic changes also occur within the maternal circulation that contribute
to hyperfiltration, the hallmark of healthy adaptation to pregnancy. These include
vasodilation, decreased systemic vascular resistance, and decreased arterial pressure,
which nadirs between 18 and 24 weeks gestation.16 Plasma volume increases by
approximately 1 L and total body water increases by 6-8 L (primarily in the extracellular
compartment), which can result in edema during pregnancy.17,18 Cardiac output increases
due to decreased afterload in this setting.16 Coinciding with these changes, renal plasma
flow increases by 80% and glomerular filtration rate increases by 40-60% by the second
half of pregnancy, clinically manifesting as a decrease in circulating creatinine, urea, and
uric acid.17 Renal plasma flow falls rapidly after 36 weeks gestation, followed by
normalization of glomerular filtration rate.19
In addition to the effect of hyperfiltration, altered tubular reabsorption is likely also
responsible for increased levels of urinary protein,20 glucose,21 and amino acids22 during
pregnancy. However, in limited studies designed primarily to determine mechanisms,
results are inconclusive and the clinical relevance of glucosuria and aminoaciduria in
pregnancy is not known. While the upper limit of normal for proteinuria in pregnancy
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cited in obstetrical guidelines is 300 mg/24-hour period, double the upper limit of normal
for the non-gravid state, significant proteinuria in pregnancy is not considered adaptive.23
Several other physiologic changes occur during pregnancy that result in mild
hyponatremia,24 mild hypokalemia,25 and chronic respiratory alkalosis.26 These, and other
anatomic and physiologic changes, typically return to pre-pregnancy state within a few
weeks postpartum.

2.2.2 Measurement of Kidney Function in Pregnancy
Hyperfiltration in pregnancy results in a physiologic decrease in serum creatinine
concentration by an average of 35 micromol/L.17 This renders estimations of glomerular
filtration rate based on serum creatinine concentration inaccurate. The Cockcroft-Gault
equation has been shown to underestimate glomerular filtration by 25% in 23% of cases
studied.27 The MDRD equation underestimated glomerular filtration by 25% in 61% of
cases studied.27 The CKD-EPI equation, which was developed to provide a more accurate
estimate of glomerular filtration among patients with higher glomerular filtration rates,28
has not been assessed in pregnancy. Measurement of creatinine clearance with a 24-hour
urine collection is also imprecise during pregnancy due to the delay between urine
formation and collection that results from urinary stasis with dilatation of the lower
urinary tract.29 Considering these limitations, assessment of kidney function in pregnancy
is restricted to examining trends in serum creatinine concentration, the interpretation of
which is also dependent on the presence of baseline measures of serum creatinine prior to
pregnancy.

2.3 Acute Kidney Injury
2.3.1 Definition of Acute Kidney Injury in the General Population
AKI is a sudden loss of kidney function, resulting in the retention of urea and other waste
products, and dysregulation of fluid and electrolytes.30 This can result from specific
diseases of the kidney (e.g., interstitial nephritis, glomerulonephritis) or extrarenal
pathology (e.g. dehydration, heart failure, sepsis, obstruction).30 In severe cases, this
manifests as metabolic acidosis, electrolyte abnormalities, fluid retention, hypertension,
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in glomerular filtration rate among women with normal or near normal values at baseline,
may not be appreciated at the time of presentation using these criteria.37 Therefore,
although a wide range of criteria have been used to define pregnancy-related AKI in
previous studies, including RIFLE criteria38 and hospital diagnosis codes,2,39,40 these
should be expected to underestimate its true incidence. Even in the general population,
hospital diagnosis codes for AKI lack sensitivity.41 At this point, the diagnosis of AKI in
pregnancy is primarily a clinical one, dependent on careful interpretation of serum
creatinine values in the context of known baseline measures of kidney function by an
astute clinician.

2.3.3 Role of Dialysis in Acute Kidney Injury
In both non-pregnant and pregnant populations, management of AKI is supportive and is
focused on identification and treatment of the underlying cause (which, depending on the
cause in pregnancy, may necessitate early delivery of the fetus).23,42 However, if
conservative therapy fails to control complications such as acidosis, hyperkalemia,
volume overload, or symptomatic uremia, dialysis may be indicated.34,42 Dialysis is a
process whereby blood is removed from the body and circulated through an
extracorporeal fluid circuit, then returned to the patient. Waste products and excess fluid
are removed from the blood via diffusion (movement of solute by concentration gradient)
and ultrafiltration (movement of fluid and solute by pressure gradient).43 There are
several risks associated with this process, including hypotension, arrhythmia, infection,
and bleeding, so clinicians tend to delay initiation of dialysis in cases where they suspect
the patient will recover on their own and complications can be managed with medical
therapy.34,43 Although the optimal timing, modality, and dose of dialysis for AKI has not
been determined in any population, these clinical indications are universally recognized
as indicators of high disease severity and are consistent with the recommendations
provided in the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice
Guideline for AKI.34,42 Literature on maintenance of pregnancy in the setting of end-stage
kidney disease suggests that there may be a role for early initiation of intensive
hemodialysis to minimize maternal complications and fetal risks from uremia (such as
polyhydramnios, preterm birth, premature rupture of membranes, and developmental
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delay),44–46 however there is no evidence that this strategy is being adopted for severe
AKI in pregnancy.42

2.4 Epidemiology of Acute Kidney Injury
2.4.1 Epidemiology of Acute Kidney Injury in the General Population
The incidence rate of AKI requiring dialysis in the general population is 24.4 per 100,000
person-years and is increasing by an average of 10% per year.36,47 In-hospital mortality is
approximately 60%.48–50 Among those who survive, as many as 15% remain on dialysis
at the time of discharge.49,51

2.4.2 Epidemiology of Acute Kidney Injury in Pregnant Populations
The true incidence of AKI in pregnancy is difficult to determine due to the inconsistency
of diagnostic criteria used to define AKI and varies considerably across populations
depending on demographics and standards of care. However, several general
epidemiologic trends can be established from existing studies.
Based on data from several diverse populations since the 1960s, the incidence proportion
of AKI in pregnancy has declined dramatically from 1 in 3,000 to 1 in 15,000-20,000
worldwide.1,52–55 Similarly, the proportion of all AKI cases accounted for by pregnancyrelated causes has dropped from 20-40% to 2-10%.1,53,54 Short-term maternal morbidity
after pregnancy-related AKI and dialysis dependence among survivors has also nearly
disappeared, previously affecting as many as 30% and 11% of cases respectively. These
trends have been closely linked to improved obstetrical care in developed countries and
dramatic reductions in first-trimester AKI attributable to fewer septic abortions with the
legalization of abortion.1
Studies that have examined secular trends of AKI in pregnancy in contemporary North
American populations have demonstrated a paradoxical increase in incidence of AKI
defined by hospital diagnosis codes (Table 2)39,40,56 which is in keeping with the trends
observed in the general population using serum creatinine-based definitions of AKI.36,47
Callaghan et al. reported a significant increase in the incidence proportion of AKI in
pregnancy in the United States between 1998 and 2008, from 2.3 to 4.5 per 10,000
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deliveries (P < 0.05).40 A similar trend was observed in Canada where the incidence
proportion of AKI in pregnancy increased from 1.6 to 2.7 per 10,000 deliveries between
2003 and 2010 (P < 0.05).39,56 This temporal increase was restricted to pregnancies
complicated by hypertensive disorders and was especially pronounced among women
with gestational hypertension and proteinuria (i.e. preeclampsia).56 These trends also
correspond to increases in the rate of deliveries among women with pre-existing medical
conditions such as hypertension, diabetes mellitus, and chronic kidney disease (known
risk factors for preeclampsia) and those with complications such as preeclampsia and
postpartum hemorrhage noted in other population-based studies.7
Table 2: Contemporary population-based studies of acute kidney injury in
pregnancy
Study
(Publication
Date)

Population
(Years)

Liu et al.39
(2010)

All hospital
deliveries in
Canada (except
Quebec)
(2003-2007)

Callaghan et
al.40 (2012)

Mehrabadi et
al.56 (2014)

All delivery and
postpartum
hospitalizations
in a stratified
sample of
community
hospitals in the
United States
(1998-2009)

All hospital
deliveries in
Canada (except
Quebec)
(2003-2011)

AKI Definition
ICD-10 diagnosis
codes for AKI
(Canadian Institute
for Health
Information –
Discharge abstract
database)
CCI procedure codes
for dialysis (Canadian
Institute for Health
Information –
Discharge abstract
database)

ICD-9 diagnosis
codes for AKI

ICD-10 diagnosis
codes for AKI
(Canadian Institute
for Health
Information –
Discharge abstract
database)

Incidence
Proportion

Associated
Conditions

1.6 to 2.3
cases/10,000
deliveries from
2003 to 2007

Not reported

0.4 to 0.4
cases/10,000
deliveries from
2003 to 2007

Not reported

2.3 to 4.5
cases/10,000
deliveries from
1998 to 2009

Not reported

1.6 to 2.7
cases/10,000
deliveries from
2003 to 2010

Age >35,
nulliparity,
multifetal gestation,
hypertension,
diabetes,
preeclampsia,
postpartum
hemorrhage, sepsis,
cardiac failure,
caesarean section
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CCI procedure codes
for dialysis (Canadian
Institute for Health
Information –
Discharge abstract
database)

10.4% to 7.6% of
AKI cases from
2003 to 2010

Not reported

2.5 Etiology of Acute Kidney Injury in Pregnancy
Clinical investigation for the cause of AKI in pregnancy is the same as in the nonpregnant population, which includes consideration of pre-renal, renal, and post-renal
etiologies.42 However, there are several conditions known to precipitate AKI that are
either unique to pregnancy or worsened by the gravid state. Unfortunately, there are
limited data on the incidence, risk factors, and outcomes of these conditions, including
the associated risk of AKI. The following three sections elaborate on three main causes of
AKI in pregnancy that can occur in the setting of many common medical or surgical
complications of pregnancy. However, much of this information is based on known
pathophysiologic mechanisms, rather than population-based studies designed to assess
the risk of AKI in these settings.

2.5.1 Ischemic Injury
Volume depletion from any cause can precipitate AKI in pregnancy through pre-renal
ischemia or acute tubular necrosis. Prior to 20 weeks gestation, this may be due to
hyperemesis gravidarum, a condition defined by refractory nausea and vomiting
accompanied by weight loss in excess of 5% of pre-pregnancy body weight, or obstetrical
hemorrhage due to a spontaneous or induced abortion.42 Later in pregnancy, cardiogenic
shock as a result of an amniotic fluid embolism, obstetrical hemorrhage from placental
abruption, or postpartum hemorrhage are more common.42 Sepsis due to
chorioamnionitis, endomyometritis, or pyelonephritis can lead to AKI in pregnancy
through similar mechanisms.42,57 Renal cortical necrosis can also occur in these settings,
however this is now almost exclusively limited to developing countries where access to
prompt obstetrical care is limited.42,58
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2.5.2 Hypertensive Disorders of Pregnancy
Preeclampsia refers to the new onset of hypertension and either proteinuria or end-organ
dysfunction after 20 weeks gestation.23 The frequency of preeclampsia ranges from 2% to
7% in healthy nulliparous women and increases substantially in women with advanced
maternal age, multifetal gestation, chronic hypertension, diabetes mellitus, and chronic
kidney disease.59,60 Preeclampsia is the leading cause of maternal morbidity and mortality
worldwide and is the most common cause of AKI during pregnancy.61 Although most
women experience only minor transient increases in serum creatinine; when accompanied
by features of HELLP syndrome (defined by the presence of hemolysis, low platelet
count, and elevated liver enzymes), AKI has been reported in 3-15% of cases.62,63 In
addition to the direct effect of preeclampsia on renal function via endothelial injury,
secondary effects of intravascular volume depletion, vasoconstriction, and activation of
inflammatory and coagulation cascades in these settings can increase the risk of kidney
failure in pregnancy.63

2.5.3 Thrombotic Microangiopathy
Although much less common, thrombotic microangiopathy is another important cause of
AKI in pregnancy; which, like preeclampsia, typically presents after 20 weeks gestation.
Thrombotic microangiopathy is a pathological process characterized by microangiopathic
hemolytic anemia, thrombocytopenia, and variable signs of organ injury from endothelial
damage and thrombosis.64 Thrombotic microangiopathy is a defining feature of
thrombotic thrombocytopenic purpura (TTP), a condition caused by a congenital or
acquired deficiency in ADAMTS13 (A Disintegrin And Metalloprotease with a
ThromboSpondin type 1 motif, member 13, an enzyme that works to minimize
microvascular thrombosis by cleaving complexes formed by von Willebrand factor and
platelets).65 However, thrombotic microangiopathies may be caused by other
mechanisms, including enteric infection with Shiga toxin (known as hemolytic uremic
syndrome [HUS]), drug-mediated toxicity or immune reaction, and complement
dysregulation (known as atypical HUS) or may be the manifestation of several other
underlying disorders in up to 60% of cases.65 Although thrombotic microangiopathy
occurs in only 1 in 25,000 pregnancies, pregnancy accounts for 10-25% of cases of
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thrombotic microangiopathy and is a known trigger for ADAMTS13 deficiency in TTP
and uncontrolled complement activation in atypical HUS.66–68 AKI is most common
among patients with atypical HUS with severe AKI requiring dialysis reported in over
80% of cases.68

2.6 Outcomes of Acute Kidney Injury in Pregnancy
In a population-based study of hospital deliveries in Canada between 2003 and 2011, the
proportion of pregnancies affected by AKI that required dialysis was 8.8% and maternal
death occurred in 2.8% of cases.56 However, based on the information provided, acute
dialysis may not have been completely captured in this study,56 and this data does not
reflect dialysis dependence among survivors. Reports of this outcome are limited to two
small studies from Brazil and Egypt, in which AKI was defined by treatment with
dialysis and RIFLE criteria within admission to the intensive care unit respectively.38,69
These studies suggest that up to 50% of women may remain dialysis dependent
postpartum and maternal death may occur in up to 30% of cases of severe AKI.38,69
However, these studies represent single-center experiences prone to selection biases. No
study to-date has examined the perinatal complications associated with AKI of any
severity in a contemporary developed population.
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Chapter 3

3

Rationale for Research Approach

3.1 The Need for Research
Several attempts have been made to understand pregnancy-related AKI in contemporary
populations.2,38–40,56,69,70 These studies have been limited by small sample sizes,38,69
highly selected populations,38,69,70 and use of definitions for AKI that have not been
validated in pregnancy and in some cases might lack clinical relevance.2,39,40,56 Trends in
older maternal age and greater chronic disease among pregnant North American women
appear to have a negative impact on the incidence of pregnancy-related AKI in
contemporary populations.7,56 How these trends impact the incidence, characteristics, and
outcomes of more severe presentations of AKI, such as those treated with acute dialysis
during pregnancy or the postpartum period, remains unclear. Small, single center studies
suggest that maternal morbidity and mortality may still be high in these cases, while
perinatal complications remain uncertain.38,69

3.2 Our Research Approach
In 2013, Ontario had a population of nearly 14 million residents with approximately
140,000 births occurring each year over the previous 5 years (2009–2013).71,72 All
permanent residents of Ontario receive universal access to hospital and physician services
from a single provincial payer. Comprehensive health administrative data collected for
this purpose is de-identified and housed in a large repository at the Institute for Clinical
Evaluative Sciences (ICES) for the purpose of health services research.73 This data can be
leveraged to conduct large population-based studies of health outcomes.
We used Ontario’s health administrative data to identify all consecutive pregnancies
between 1997 and 2011 and describe the incidence, characteristics, and outcomes of AKI
treated with dialysis (AKI-D) during pregnancy or the postpartum period using
administrative data from several sectors of health care.
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3.2.1 Strengths of Ontario’s Health Administrative Data
There are several advantages to using this data. Ontario’s health administrative databases
are large and provide the opportunity to identify populations retrospectively with minimal
selection bias and loss to follow-up (only by emigration out of the province, which is less
than 0.5% per year), ensuring high generalizability.74 Access to large population-based
cohorts through this strategy also allows researchers to examine rare events such as AKI
in pregnancy with high statistical power, low cost, and limited time. Because data from
several sectors of health care (vital statistics, physician services, hospital records,
medications) can be linked, a wide range of variables can be ascertained. Many of these
variables, including those used to study AKI in pregnancy, have proven valid in previous
studies.75–83 In addition, because maternal hospital records can be linked to infant hospital
records, there is a unique opportunity to examine perinatal characteristics not addressed
in previous studies.

3.2.2 Limitations of Ontario’s Health Administrative Data
However, administrative data is limited by its primary purpose, which is to guide
remuneration and resource allocation. As a result, there are information gaps in history
and physical examination variables, laboratory data, and medication use for those under
the age of 65.73 Further, although some administrative data codes have been validated for
use in research, the majority have not. Many coding algorithms lack sensitivity and
misclassification of variables can occur. This misclassification is typically ‘nondifferential’, as acquisition of data is independent of the research question and not subject
to recall bias, and should be expected to bias of the estimate of effect towards the null
hypothesis (Type II error) and/or result in suboptimal control of confounding variables.84
Medical procedures are generally considered more reliable than diagnoses obtained from
medical records given the financial incentives and processes in place to submit and
encode data.84

3.3 Challenges of Pregnancy Outcomes Analyses
There are several analytic challenges to consider when conducting population-based
pregnancy outcome studies. First, administrative data sources in Canada only capture
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pregnancies resulting in childbirth (live or stillborn), so pregnancies resulting in a
spontaneous or therapeutic abortion prior to 20 weeks gestation (which may occur in up
to 25% of pregnancies) are not captured.85 Second, because women may have several
pregnancies during the data accrual period, exposure and outcome data may be clustered
by mother if pregnancy is used as the unit of analysis. Failure to account for this
intracluster correlation may bias the estimate of effect towards rejecting the null
hypothesis (Type I error).86 However, several modeling approaches may be used to
address this.86,87 Third, because pregnancy is often the first healthcare encounter for
women included in these studies, data on preexisting conditions may not have been
captured in administrative data. This may result in misclassification of pre-pregnancy
conditions as pregnancy-related if identified during prenatal care.
Finally, while there are several conditions known to be associated with AKI in
pregnancy,56 the relationship between pre-pregnancy maternal characteristics, medical
complications of pregnancy, and adverse maternal and perinatal outcomes is complex.
Many of these variables are highly correlated and there is limited data to support
assumptions about the pathophysiologic pathway that represents the relationship between
suspected risk factors, confounders, and outcomes, and the directionality of these
associations. This makes it difficult to adequately control for confounding and, in some
cases, even assign labels such as ‘exposure’ and ‘outcome’. For example, consider the
proposed association between preeclampsia, AKI, and preterm birth highlighted in Figure
1 (oversimplified for demonstration purposes).
Figure 1: Potential causal pathways for the association between preeclampsia, AKI,
and preterm birth
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Depending on the causal pathway of interest, AKI may be a ‘mediator’ of the association
between preeclampsia and preterm birth, a ‘confounder’ if not actually on the causal
pathway between preeclampsia and preterm birth, or an ‘exposure’ relative to
preeclampsia or preterm birth. Further, preterm birth could actually precede the clinical
diagnosis of preeclampsia and/or AKI if there is an another 'exposure' (risk factor or
characteristic) at play. This other exposure, such as the condition lupus nephritis, may act
both as a cause of preterm birth and a risk factor for either preeclampsia, AKI, or both.
This would reverse the sequence of identification of events, but would not necessarily
mean that preterm birth caused preeclampsia or AKI. For this reason, the purpose of this
study was not to establish causality, but rather to determine the direction and magnitude
of associations in order to create a framework for physicians to better identify women at
risk.
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4.2 Research Framework
In order to address these questions, we conducted a retrospective population-based cohort
study of all consecutive pregnancies resulting in childbirth over a 15-year period (19972011) in Ontario, Canada to identify incident cases of AKI-D during pregnancy or the
postpartum period, determine the concurrent maternal complications that may be
associated with AKI-D, and examine perinatal complications and maternal outcomes in
relation to AKI-D.
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Chapter 5

5

Methods

5.1 Design and Setting
We conducted a retrospective population-based cohort study using linked healthcare
databases in Ontario, Canada to study the incidence, characteristics, and outcomes of
AKI-D in pregnancy and the postpartum period. Study conduct and reporting follow
guidelines (STROBE) for observational studies (Appendix A).88

5.2 Ethics
A research ethics board at Sunnybrook Health Sciences Centre in Toronto approved the
pre-specified protocol (Appendix B and C). However, numbers of participants were
suppressed in the case of five or fewer participants (reported as ≤ 5) to comply with
privacy regulations for minimizing the chance of identification of a study participant.

5.3 Data Sources
5.3.1 Databases
We identified our pregnant population by childbirth and ascertained maternal and
perinatal characteristics and outcome data from records in seven linked databases from
the Institute of Clinical Evaluative Sciences (ICES). Vital statistics and location of
residence were obtained from the Registered Persons Database, which contains
demographic information for all Ontario residents ever issued a health card.73 We used
inpatient and outpatient diagnostic and procedural information to define maternal
characteristics and outcome data. The Canadian Institute for Health Information
Discharge Abstract Database (CIHI-DAD) collects demographic, diagnostic, and
procedural variables for all acute care, chronic, and day surgery admissions.73 The
Ontario Health Insurance Plan (OHIP) database contains fee-for-service claims for
inpatient and outpatient physician services.73 Each claim record includes information
about the physician, service provided, and diagnostic information. Diabetic and
hypertensive patients were identified using the Ontario Diabetes Database and the
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Ontario Hypertension Database. These databases are derived by ICES and use a validated
algorithm to identify diabetic and hypertensive patients based on data from CIHI-DAD
and OHIP.76,77 Childbirths and perinatal characteristics were identified using the
MOMBABY dataset. This is also an ICES-derived dataset that links the CIHI-DAD
inpatient admission records of delivering mothers and their newborns.73 Maternal cause
of death was determined from the Ontario Registrar General Death database, which
contains information on all deaths registered in Ontario.73 Members of our research team
have used these databases in previous studies to research health outcomes and health
services including those related to AKI-D.89–92 Ascertainment of variables from these
databases were complete, with minor exceptions detailed in Table 5.
Table 5: Missing data for cohort of 1,918,789 pregnancies resulting in childbirth,
1997 to 2011
Database

Dates Available

Dates Required

Dates Missing

Data Affected

OHIP

July 1991 to
March 2012

April 1991 to
March 2012

April 1991 to
June 1991

Incomplete capture of prepregnancy chronic kidney disease
in the 5-years prior to pregnancy for
childbirths between January 1997
and March 1997.

ORGD

January 1990 to
December 2009

January 1997 to
March 2012

January 2010 to
March 2012

Missing cause of death for
childbirths resulting in maternal
death between January 2010 and
March 2012.

RPDB

April 1990 to
March 2012
(Incomplete)

January 1997 to
March 2012

January 1997 to
March 2012
(Selected Data)

Missing income quintile in 9851
(0.51%) childbirths and rural
residence in 2488 (0.13%)
childbirths between January 1997
and March 2012.

Abbreviations: OHIP, Ontario Health Insurance Plan using fee and diagnostic codes; RPDB, Registered Persons
Database; ORGD, Ontario Registrar General Death database.

5.3.2 Codes
In Ontario, hospital admissions were coded using the International Classification of
Diseases, Ninth Revision (ICD-9) (including Canadian Classification of Diagnostic,
Therapeutic, and Surgical Procedures [CCP]) prior to April 2002 and the International
Classification of Diseases, Tenth Revision (ICD-10) (including Classification of Health
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Maternal Characteristics Prior to Pregnancy †
Age

RPDB

N/A

Neighborhood income

RPDB

N/A

Rural residence

RPDB

N/A

Previous pregnancy ‡

MOMBABY

MOMBABY: [B_BDATE] in the infant CIHI-DAD record

Hypertension

OHD §

N/A

Diabetes mellitus

ODD ||

N/A

Chronic kidney
disease

CIHI-DAD
OHIP

ICD-9: 4030, 4031, 4039, 4040, 4041, 4049, 582, 583, 580,
581, 584, 585, 586, 587, 5880, 5888, 5889, 5937
ICD-10: E102, E112, E132, E142, I12, I13, N08, N18, N19
OHIP: 403, 585

General practitioner
/Family physician

IPDB

N/A

Internal medicine
specialist

IPDB

N/A

Nephrologist ¶

OHIP

OHIP: C132, C101, C138, G860, G323, E083, C137, C135,
A135

Maternal Complications During Pregnancy or the Postpartum Period **
Multifetal gestation

MOMBABY

MOMBABY: [B_MULTIPLE BIRTH] or [M_MULTIPLE
BIRTH] in the infant/maternal CIHI-DAD record

Hyperemesis
gravidarum

CIHI-DAD
OHIP

ICD-9: 64300, 64301
ICD-10: O21001, O21003, O21009, O21101, O21103, O21109
OHIP: 643

Gestational
hypertension

CIHI-DAD

ICD-9: 64290, 64291, 64292, 64293, 64294
ICD-10: O13

Preeclampsia
(includes eclampsia)

CIHI-DAD
OHIP

ICD-9: 64240, 64241, 64242, 64243, 64244, 64250, 64251,
64252, 64253, 64254, 64260, 64261, 64262, 64263, 64264,
64270, 64271, 64272, 64273, 64274
ICD-10: O14, O15
OHIP: 642

Thrombotic
microangiopathy ††

CIHI-DAD
OHIP

ICD-9: 4466
ICD-10: M311
OHIP: 287

Plasma exchange ††

OHIP

OHIP: G272, G277, G278, G290

Pyelonephritis

CIHI-DAD
OHIP

ICD-9: 59000, 59001, 59010, 59011, 5902, 59080, 59081, 5909
ICD-10: N110, N111, N151, O23001, O23002, O23003,
O23004, O23009
OHIP: 590
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Sepsis

CIHI-DAD
OHIP

ICD-9: 0031, 0380, 0381, 0382, 0383, 03840, 03841, 03842,
03843, 03844, 03849, 0388, 0389, 0545, 65930, 65931, 65933
ICD-10: A400, A401, A402, A403, A408, A409, A410, A411,
A412, A413, A414, A4150, A4151, A4152, A4158, A4159,
A4180, A4188, A419, R572, O85002, O85004, O85009
OHIP: 038

Caesarean delivery

CIHI-DAD

ICD-9: 66970, 66971
ICD-10: P034
CCP: 860, 861, 862
CCI: 5MD60AA, 5MD60CB, 5MD60CC, 5MD60CD,
5MD60CE, 5MD60CF, 5MD60CG, 5MD60JW, 5MD60JX,
5MD60JY, 5MD60JZ, 5MD60KA, 5MD60KB, 5MD60KC,
5MD60KD, 5MD60KE, 5MD60KF, 5MD60KG, 5MD60KT,
5MD60RA, 5MD60RB, 5MD60RC, 5MD60RD, 5MD60RE,
5MD60RF, 5MD60RG, 5MD60RH

Postpartum
hemorrhage

CIHI-DAD
OHIP

ICD-9: 66600, 66602, 66604, 66610, 66612, 66614, 66620,
66622, 66624
ICD-10: O72
OHIP: 666

Low birth weight

MOMBABY

MOMBABY: [WEIGHT] < 2500g in infant CIHI-DAD record

Small for gestational
age (includes
intrauterine growth
restriction)

CIHI-DAD

ICD-9: 65650, 65651, 65653, 76400, 76401, 76402, 76403,
76404, 76405, 76406, 76407, 76408, 76409, 76410, 76411,
76412, 76413, 76414, 76415, 76416, 76417, 76418, 76419,
76490, 76491, 76492, 76493, 76494, 76495, 76496, 76497,
76498, 76499
ICD-10: P0590, P0591, P0599

Preterm birth

MOMBABY

MOMBABY: [B_GESTWKS_DEL] or [M_GESTWKS_DEL]
< 37 weeks in infant/maternal CIHI-DAD record
ICD-9: 76500, 76501, 76502, 76503, 76504, 76505, 76506,
76507, 76508, 76509, 76510, 76511, 76512, 76513, 76514,
76515, 76516, 76517, 76518, 76519
ICD-10: P070, P071, P072, P073
OHIP: 765
[ICD-9 and ICD-10 codes were used to define preterm birth
when infant data from MOMBABY dataset was missing]

Stillbirth

MOMBABY

MOMBABY: [B_STILLBIRTH] or [M_STILLBIRTH] in
infant/maternal CIHI-DAD record

Perinatal mortality

MOMBABY

MOMBABY: [DTHDATE] within 7 days of birth in infant
RPDB record or [B_STILLBIRTH] or [M_STILLBIRTH] in
infant/maternal CIHI-DAD record

Neonatal death

MOMBABY

MOMBABY: [DTHDATE] within 28 days of birth in infant
RPDB record

Perinatal Complications
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Abbreviations: CIHI-DAD, Canadian Institute for Health Information Discharge Abstract Database using International
Classification of Disease, Ninth Revision (ICD-9) and Tenth Revision (ICD-10), Canadian Classification of Diagnostic,
Therapeutic, and Surgical Procedures (CCP), and Classification of Health Interventions (CCI) codes; OHIP, Ontario
Health Insurance Plan using fee and diagnostic codes; RPDB, Registered Persons Database; OHD, Ontario
Hypertension Database; ODD, Ontario Diabetes Database; N/A, Not applicable.
* Variables are defined by the presence of at least one of the listed codes unless otherwise specified.
† Information on preexisting medical conditions and consultations was ascertained from administrative database
codes in the five years prior to pregnancy. Age, neighborhood income, and rural residence were ascertained at time
of delivery.
‡ Information on previous pregnancies was available since 1991 and included all pregnancies in Ontario resulting in
live birth or stillbirth after 20 weeks gestation.
§ The Ontario Hypertension Database is an ICES-derived database that contains all Ontario hypertension patients
defined by a) one hospital admission with a hypertension diagnosis, or b) an OHIP claim with a hypertension
diagnosis followed within two years by either an OHIP claim or a hospital admission with a hypertension
diagnosis.76
|| The Ontario Diabetes Database is an ICES-derived database that contains all Ontario diabetes patients defined by
the presence of at least one hospital admission with a diabetes diagnosis or an OHIP claim with a diabetes
diagnosis.77
¶ Restricted to physicians who also billed at least 50 dialysis codes (one per day) within one year of consultation
service date.
** Information on medical complications of pregnancy were ascertained from administrative database codes during
pregnancy and the postpartum period.
†† The variable ‘thrombotic microangiopathy treated with plasma exchange’ was defined by receipt of plasma
exchange that falls within an admission for thrombotic microangiopathy (using CIHI-DAD codes) or within seven
days of a diagnosis of thrombotic microangiopathy (using OHIP codes).

5.3.3 Validity
Whenever possible, we defined maternal characteristics, medical complications of
pregnancy, and maternal and perinatal outcomes using database codes that have been
proven feasible and reliable in prior studies. Operating characteristics for the codes used
to define variables where validity studies exist are shown in Table 7. ICD-10
implementation in 2002 did not significantly alter coding practices for common comorbid
conditions used in risk assessment in Ontario.93,94
Table 7: Operating characteristics of codes used to define variables where validity
studies exist.
Operating
Characteristics
Codes
Used in
Study

Codes
Used in
Validation

Preterm birth

P070
P071
P072
P073

P070
P071
P072
P073

Caesarean
delivery

P034

P034

Outcome

Sn
(%)

Sp
(%)

PPV
(%)

Identification of preterm delivery as
ascertained through chart review by
trained personnel.75

91.2

98.8

…

Identification of caesarean delivery as
ascertained through chart review by

99.8

98.7

…

Gold Standard
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trained personnel.75
Gestational
hypertension

O13

O13

Identification of gestational
hypertension as ascertained through
chart review by experienced
clinicians.79,80

10.068.2

99.699.8

…

Preeclampsia

64240
64241
64242
64243
64244
64250
64251
64252
64253
64254
64260
64261
64262
64263
64264
64270
64271
64272
64273
64274

6424

78.4

64.3

45.3

66.7

85.0

84.8

83.3

94.6

41.7

100.0

100.0

100.0

76.0

…

94.0

O14
O15

O14
O15

Identification of ‘mild or unspecified
preeclampsia’ on chart review by
obstetricians using criteria
established by the American College
of Obstetrics and Gynecology.81
Identification of ‘severe
preeclampsia’ on chart review by
obstetricians using criteria
established by the American College
of Obstetrics and Gynecology.81
Identification of ‘eclampsia’ on chart
review by obstetricians using criteria
established by the American College
of Obstetrics and Gynecology.81
Identification of ‘severe preeclampsia
and eclampsia’ on chart review by
obstetrician.82
Identification of ‘preeclampsia’ on
chart review by experienced
accredited record technicians or
certified coding specialists.83
Identification of ‘preeclampsia’ on
chart review using a well-described
and accepted definition.80

69.3

99.3

74.4

Placental
Abruption

64120
64121
64123

64120
64121
64123

Identification of placental abruption
as ascertained through chart review
by experienced accredited record
technicians or certified coding
specialists.83

89.0

…

89.0

Postpartum
hemorrhage

O72

O72

Identification of postpartum
hemorrhage as ascertained through
chart review by trained personnel.75

90.2

98.2

…

Chronic
kidney
disease

*

*

*

…

…

…

6425

6426

6425
6426
6425
6427

Abbreviations: Sn, Sensitivity (indicates the percentage of women with the condition who are correctly identified as
having the condition); Sp, Specificity (indicates the percentage of healthy women who are correctly identified as not
having the condition); PPV, Positive predictive value (indicates the percentage of women whose diagnosis is recorded
correctly). Ellipses indicate data not reported.
* Chronic kidney disease was defined using an algorithm of hospital diagnosis codes validated for older adults in the
study region.78 This algorithm identified patients with a median estimated glomerular filtration rate of 38
mL/min/1.73 m2 (interquartile range, 27 to 52 mL/min per 1.73 m2), whereas its absence identified patients with a
median estimated glomerular filtration rate of 69 mL/min/1.73 m2 (interquartile range, 56 to 82 mL/min per 1.73
m2).78
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These coding algorithms were validated against a gold standard from chart review, which
in many cases, was performed by a clinician using a well-described and accepted
definition of the condition. These coding algorithms have high specificity and high
positive predictive value. Sensitivity appears greatest for coding algorithms used to
identify more severe disease. However, the operating characteristics reported in Table 7
apply only to the coding algorithm specified and do not necessarily reflect the entire
collection of codes used to define characteristics and outcomes in our study. Therefore,
these statistics should only be used as a reference source from which the actual operating
characteristics of coding algorithms used in this study can be approximated. Our rationale
for including codes not previously validated was to improve sensitivity for capture of that
variable.

5.4 Population
Ontario provides universal access to hospital and physician services for all permanent
residents, with about 140,000 births per year over the previous 5 years (2009-2013).71 We
established a cohort of all pregnancies resulting in childbirth between January 1, 1997,
and December 31, 2011. Our data sources capture all hospital childbirths in the province,
defined as delivery of an infant at a gestational age of ≥ 20 weeks.95,96
We applied several data cleaning steps to ensure that (1) both maternal and perinatal data
could be ascertained for each pregnancy, (2) all pregnancies were among live women of
childbearing age, and (3) multiple gestations were not counted as more than one
pregnancy.
We assigned an index date to each pregnancy that was 42 weeks prior to delivery. This
was used to define the onset of pregnancy and served as a reference point from which a
lookback window for assessment of maternal and perinatal characteristics and an
outcome assessment window could be defined. We used 42 weeks prior to delivery, the
longest term gestational duration, for this purpose to avoid misclassification of conditions
identified early in pregnancy as pre-pregnancy conditions. When relevant, the index date
marked the onset of the first trimester, the index date plus 12 weeks (and 1 day) marked
the onset of the second trimester, and the index date plus 27 weeks (and 1 day) marked
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the onset of the third trimester. The postpartum period was defined by the 12 weeks after
the delivery date.
We then excluded pregnancies among mothers with a history of end-stage kidney disease
(defined as chronic dialysis treatment or kidney transplantation) within 5 years prior to
the index date as these women would already have experienced one of the maternal
outcomes of interest prior to pregnancy.

5.5 AKI-D
We defined AKI-D as receipt of at least one acute dialysis treatment during pregnancy or
within 12 weeks postpartum.

5.6 Maternal Characteristics
5.6.1 Maternal Characteristics Prior to Pregnancy
We collected information on the following maternal characteristics at the time of
delivery, assuming that this data would approximate status at the estimated beginning of
pregnancy: age, neighborhood income quintile, and location of residence. We collected
information on the following characteristics prior to pregnancy using a fixed lookback
window of 5 years prior to the index date: number of previous pregnancies, time since
previous pregnancy, presence of preexisting hypertension, diabetes mellitus, and chronic
kidney disease, and previous physician visits with a general practitioner or family
physician, internal medicine specialist, and nephrologist. This lookback window was
fixed to avoid information bias based on cohort entry date.

5.6.2 Maternal Complications During Pregnancy or the Postpartum
Period
We collected information on medical complications during pregnancy or within 12 weeks
postpartum (complications such as preeclampsia may occur up to 12 weeks
postpartum).97 These included multifetal gestation, hyperemesis gravidarum, gestational
hypertension, preeclampsia, thrombotic microangiopathy, pyelonephritis, sepsis,
caesarean delivery, and postpartum hemorrhage.
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5.7 Perinatal Complications
We collected data on the following perinatal complications at the time of delivery and up
to (and including) 28 days after delivery: low birth weight (< 2500 g irrespective of
gestational age), small for gestational age (birth weight < 10th percentile for gestational
age), preterm birth (birth of a live infant before 37 weeks gestation), stillbirth (fetal death
after 22 weeks gestation), perinatal mortality (stillbirth or death of a live-born infant
within 7 days) and neonatal death (death of a live-born infant within 28 days).98–101

5.8 Maternal Outcomes
Maternal outcomes included (1) maternal death on or before 90 days after the date of
delivery, and (2) chronic dialysis dependence, defined as the receipt of two or more
chronic dialysis treatments between 90 and 120 days (17 weeks) after the date of delivery
among survivors of AKI-D.

5.9 Statistical analyses
Pregnancy was the unit of analysis in this study. In order to evaluate the extent of withinmother clustering, we first quantified the number of pregnancies resulting in childbirth
during our accrual period and the number of unique mothers.
We then determined the proportion of pregnancies affected by AKI-D during the accrual
period (also referred to as the incidence proportion) and described the maternal
characteristics prior to delivery in relation to AKI-D status. We used standardized
differences to compare maternal characteristics in pregnancies with and without AKI-D.
Standardized differences are less sensitive to sample size than traditional hypothesis tests
and are not affected by clustering. They provide a measure of the difference between
groups divided by the pooled standard deviation; a value of ≥ 0.10 (10%) is interpreted as
a meaningful difference between groups.102
We examined the association between maternal complications during pregnancy or the
postpartum period and the incidence of AKI-D using generalized estimating equations
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and log-binomial models to estimate the relative difference in the proportion of
pregnancies affected by AKI-D among those with maternal complications compared to
those without maternal complications, and reported the unadjusted incidence proportion
ratios and 95% confidence intervals.
We examined the association between AKI-D during pregnancy or the postpartum period
and the incidence of perinatal complications similarly using generalized estimating
equations and log-binomial models to estimate the relative difference in the proportion of
pregnancies resulting in perinatal complications among those with AKI-D compared to
those without AKI-D, and again reported the unadjusted incidence proportion ratios and
95% confidence intervals.
We then used generalized estimating equations and log-binomial models to estimate the
relative difference in the risk of maternal death among those with AKI-D compared to
those without AKI-D. We reported the proportion of pregnancies resulting in maternal
death among those with and without AKI-D, the absolute risk difference, unadjusted
relative risk with the 95% confidence interval, and the P value for the difference in
unadjusted relative risk. We set the level of significance at P < 0.05.
All analyses were unadjusted due to the small sample size in the AKI-D group, limited
data to support assumptions about independence of maternal characteristics from the
causal pathway between complications and maternal outcomes, and lack of sensitivity of
our data sources for capture of these variables. We used log-binomial models to reflect
the binomial distribution of outcomes with a log-link function to estimate incidence
proportion ratios and relative risks.103 Generalized estimating equations were used to
account for within-mother clustering from additional pregnancies during follow-up. This
model assumes that clusters are independent and that the correlation matrix that
represents the within-subject dependencies is estimated as part of the model (which in
this case, assumes that the correlation is the same for all pregnancies that share the same
mother, regardless of birth sequence).104 This model is ideal for analyses of many small
clusters and is robust even if the working correlation structure is misspecified.87
All analyses were conducted using SAS, version 9.3 (SAS Institute Inc., Cary, NC).
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Chapter 7

7

Discussion

7.1 Main Findings
In this study of 1.9 million pregnancies over a 15-year period, 1 in 10,000 pregnancies
were affected by AKI-D. Most women who developed AKI-D had no record of a
preexisting chronic medical condition such as hypertension, diabetes, or chronic kidney
disease. Several maternal complications were associated with a higher incidence of AKID in pregnancy or the postpartum period. These included preeclampsia, thrombotic
microangiopathy, pyelonephritis, sepsis, caesarean delivery, and postpartum hemorrhage.
AKI was associated with a higher incidence of adverse perinatal complications including
low birth weight, small for gestational age, and preterm birth, however there were no
stillbirths and no more than five neonatal deaths (< 3%) in affected pregnancies. Maternal
mortality after AKI-D was 4%, and 4% of survivors remained dependent on dialysis after
delivery.

7.2 Comparison with Other Studies
7.2.1 Incidence of AKI-D
Most population-based reports on pregnancy-related AKI refer exclusively to secular
trends in infection-related first-trimester AKI, coinciding with the legalization of abortion
and improved obstetrical care in low-income countries.1,52–55 Pregnancies in high-income
regions are more frequently complicated by hypertensive disorders of pregnancy,
gestational diabetes, and postpartum hemorrhage, whereas genitourinary and obstetric
infections appear to be on the decline.7 More recent North American studies examining
the impact of these trends on AKI defined by hospital diagnosis codes, indicate a
paradoxical increase in the incidence of AKI in pregnancy from what was previously
reported, with an incidence proportion of approximately 2 in 10,000 deliveries.39,40,56 This
trend has been attributed to the increasing incidence of hypertensive disorders of
pregnancy in these populations.56 While AKI-D occurred much less frequently in our
population (1 in 10,000 deliveries), our data suggest that these complications, alone or in
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combination with other risk factors, may occur in a setting necessitating acute dialysis as
well.

7.2.2 Maternal Complications Associated with AKI-D
Trends indicating an increasing incidence of AKI in North America appear to correspond
to increases in the rate of deliveries among women at advanced maternal age or with preexisting medical conditions such as hypertension, diabetes mellitus, and chronic kidney
disease (known risk factors for preeclampsia)59,60 and those with complications such as
preeclampsia and postpartum hemorrhage noted in other population-based studies.7
These, and other complications including sepsis, cardiac failure, and caesarean section
have been confirmed to be associated with AKI in pregnancy, however the temporal
increase in AKI in pregnancy reported in previous North American studies appears to be
restricted to pregnancies complicated by hypertensive disorders, and was especially
pronounced among women with preeclampsia.56
Women who developed AKI-D in our cohort were generally healthy with few recorded
pre-existing medical conditions. However, as the prevalence of preexisting medical
conditions in our study was likely underestimated, women with chronic hypertension and
preexisting chronic kidney disease may drive a greater proportion of AKI-D events than
realized herein.7,8 In addition to preeclampsia, we identified several other maternal
characteristics that alone or in combination may be associated with an increased
incidence of AKI-D. These include thrombotic microangiopathy, pyelonephritis, sepsis,
caesarean delivery, and postpartum hemorrhage. While it was beyond the scope of this
research to determine the nature of these associations, many of these complications have
been highlighted as associative factors in previous studies and could be assumed to be
either directly causal of AKI (eg. preeclampsia, thrombotic microangiopathy,
pyelonephritis, sepsis, postpartum hemorrhage) or occur as a result of the AKI episode or
its complications (eg. caesarean delivery), based on known pathophysiologic mechanisms
of AKI.38,56,69
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7.2.3 Perinatal Complications of AKI-D
No prior studies have assessed the incidence of perinatal complications in relation to
pregnancy-related AKI; therefore it is unclear whether associated perinatal complications
such as low birth weight, small for gestational age, and preterm birth may be attributed to
the AKI-D event itself or to associated acute medical complications. Further, it is
impossible to separate out the effect of AKI from the dialysis treatment with our data.
However, early delivery as a result of deteriorating maternal condition and altered
uteroplacental hemodynamics could explain this finding in either case.105

7.2.4 Maternal Outcomes of AKI-D
Recent reports of severe cases of pregnancy-related AKI are limited to two small studies
from Brazil and Egypt, in which AKI was defined by treatment with dialysis and RIFLE
criteria within admission to the intensive care unit respectively.38,69 These studies suggest
that maternal mortality may be as high as 30% in more severe cases of AKI, with up to
50% of women remaining dependent on dialysis after delivery.38,69 In contrast to these
studies, our data suggest that although AKI events during pregnancy do occur more
frequently in the context of acute medical complications, the impact may be short-lived.
Maternal mortality in our study was only 4.3% (compared with 0.01% in the general
population) and fewer than 4% of survivors were dependent on dialysis after 12 weeks
postpartum. Accounting for differences in severity of AKI, this is in keeping with the
2.8% incidence proportion of maternal death reported in previous population-based
studies of AKI in pregnancy in Canada.56 However, dialysis dependence was not assessed
in these studies.
Although our results support a strong association between AKI-D and maternal mortality,
the absolute risk of death is low. This, and the low proportion of survivors remaining
dialysis dependent, should be viewed as reassuring when considering the overall impact
of AKI-D on the population. Interpretation of the relative differences in risk of maternal
mortality in this setting would require further exploration of the causal association
between AKI-D and mortality, which was beyond the scope of this study.
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7.3 Strengths
The lack of a consensus definition for AKI in pregnancy and variations in demographics
and standard of care among populations has made estimation of the current incidence of
pregnancy-related AKI from epidemiologic studies difficult.1,39,40,52–56 Efforts to examine
the maternal and perinatal complications in relation to pregnancy-related AKI in
contemporary population-based cohorts is limited.39,40,56 To our knowledge, this is the
first population-based study to characterize the incidence of AKI-D in pregnancy and its
correlates and outcomes in a developed nation without apparent selection bias or loss to
follow-up, containing over three times the number of cases treated with dialysis as in
other reports.69 We were able to do this by using novel linkages between maternal and
infant administrative data.

7.4 Limitations
The limitations of this study are outlined below.

7.4.1 Generalizability
The definition of AKI was restricted to those treated with dialysis, so these results may
not apply to less severe presentations of AKI in pregnancy. Further, because the analytic
cohort was limited to pregnancies that resulted in a live birth or stillbirth after 20 weeks
gestation, study results are not generalizable to pregnancies resulting in an early
pregnancy loss.

7.4.2 Information Bias
The presence and strength of associations observed in epidemiologic studies are a
function of the validity of study variables. We conducted our analysis using hospital
diagnostic and physician billing codes from administrative data. Our strategy for
identifying many of the maternal indicators with these codes may lack sensitivity and,
therefore, underestimate their true prevalence. In most cases, misclassification of these
variables is expected to be non-differential as it is independent of AKI-D status and
would be expected to bias measures of association between the presence (vs. absence) of
these characteristics and incidence of AKI-D towards the null hypothesis (Type II
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error).84 Although some coding algorithms may also lack specificity. For example, codes
used to ascertain ‘thrombotic microangiopathy’ may capture cases of preeclampsia and
HELLP syndrome, in addition to thrombotic thrombocytopenic purpura, given the lack of
specificity of both the terminology and codes.
Assuming a 42-week gestation for the purposes of defining the onset of pregnancy may
have contributed to misclassification of pre-pregnancy maternal characteristics as
pregnancy-related complications for preterm deliveries. However, most maternal
characteristics ascertained during pregnancy are complications (and codes) specific to
pregnancy (eg. multifetal gestation, hyperemesis gravidarum, gestational hypertension,
preeclampsia, thrombotic microangiopathy) or would be expected to preclude conception
of a viable pregnancy (eg. thrombotic microangiopathy, pyelonephritis, sepsis).
Therefore, this misclassification should be limited.
Additional sources of information bias include lack of access to clinical parameters at the
time of dialysis initiation, including renal function, blood pressure, and basis for starting
or stopping dialysis, so women with progressive chronic kidney disease initiating dialysis
electively during pregnancy to optimize maternal and fetal wellbeing could have been
misclassified as having AKI-D in this study. However, the low prevalence of preexisting
chronic kidney disease and low proportion of women that remained dialysis dependent
postpartum suggests that this was infrequent. Further, defining AKI by treatment with
dialysis precludes our ability to isolate the independent effects of AKI from the dialysis
treatment itself.

7.4.3 Confounding
There are several associations noted in this study that could be explored further. These
include associations between various medical complications of pregnancy and the
incidence of AKI-D, AKI-D and the incidence of various perinatal complications, and
AKI-D and the risk of adverse maternal outcomes. However, as described in Section 3.3,
the complex (and in many cases, causal) relationship between pre-pregnancy maternal
characteristics, medical complications of pregnancy, perinatal complications, and adverse
maternal outcomes precludes our ability to isolate potential confounders to incorporate
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into multivariable logistic regression models to further explore these associations.
Further, our study was underpowered for such analyses due to the low event rate of AKID in our cohort and lack of sensitivity of coding algorithms used to ascertain maternal
characteristics of interest. For this reason, results of these analyses should be viewed as
hypothesis generating and confirmed in future studies.

7.5 Recommendations for Future Research
As a direct extension of this research, additional studies could be performed to confirm
the independent association between several maternal characteristics in this study and the
risk of AKI in pregnancy. However, there are several other knowledge gaps in this area
that warrant further attention. Additional research is needed to establish a method of early
and specific diagnosis of AKI in pregnancy, perhaps using renal biomarkers that are
independent of serum creatinine, a late indicator of acute kidney injury in pregnancy.106
Finally, although experience from treatment of pregnant women with end-stage renal
disease suggests that intensified hemodialysis and frequent maternal and fetal
surveillance might be the key to further improving maternal and perinatal outcomes in
AKI settings as well, the threshold for initiation needs further consideration.
Unfortunately, given the infrequency with which this condition occurs, it is unlikely there
will ever be controlled trials in this area. Large observational studies using administrative
data or a network meta-analysis, combining administrative data from multiple provinces,
could be used to provide insight into this treatment decision.

7.6 Conclusion
This study confirms that AKI treated with dialysis in pregnancy is rare and typically
occurs in otherwise healthy women who acquire a major pregnancy-related medical
condition. While assessment for comorbid conditions such as hypertension, diabetes, and
chronic kidney disease, remains central to identifying women at risk for hypertensive
disorders of pregnancy, our data suggest that severe AKI may be occurring through a
variety of physiologic mechanisms that may not be predictable from pre-pregnancy
health status. Fortunately, with ongoing improvements in obstetrical care,
multidisciplinary approaches, and new insights into the diagnosis and management of
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associated conditions such as preeclampsia, maternal and perinatal mortality in this
setting are largely avoidable. Knowledge of associated characteristics and outcomes
presented in this study provide important prognostic information for patients and a
framework for physicians to understand severe pregnancy-related AKI in the current era
and inform strategies that better identify women at risk.
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•
Mean (SD)
•
Median (25th, 75th percentile)
•
Range (Min – Max)
6. Hypertension, within 5 years prior to index date
7. Diabetes mellitus, within 5 years prior to index date
8. Chronic kidney disease, within 5 years prior to index date
9. General practitioner/family physician consultation, within 5 years prior to index
date
10. Internal medicine specialist consultation, within 5 years prior to index date
11. Nephrologist consultation, within 5 years prior to index date
Maternal Characteristics During Pregnancy or the Postpartum Period
To be determined between the index date and 12 weeks after delivery date.
1. Multifetal gestation, defined by [m_multiple birth=T or b_multiple birth=T] in
mother or infant record in MOMBABY dataset. All other pregnancies are
assumed to be singletons.
2. Hyperemesis gravidarum
3. Gestational hypertension
4. Preeclampisa
5. Thrombotic microangiopathy
6. History of thrombotic microangiopathy (TMA) requiring plasma exchange,
defined by any of the following:
a) The receipt of PLEX (by OHIP fee codes) that falls within an admission for
TMA (using CIHI codes)
b) The receipt of PLEX (by OHIP fee codes) that is preceded by a TMA code
(using OHIP dx codes) within 7 days. Use the PLEX code that is closest to
the TMA code to define this interval.
c) The receipt of PLEX (by OHIP fee codes) that is preceded by a TMA code
(using OHIP dx codes) within 7 days. Use the PLEX code that is closest to
the TMA code to define this interval.
6. Pyelonephritis
7. Sepsis
8. Caesarean delivery
9. Postpartum hemorrhage
Perinatal Characteristics
Differences in infant birthdate exist between MOMBABY and RPDB – selected
MOMBABY to define infant birthdate given many missing b_ikns required to link to
RPDB
1. Low birthweight: Defined by a weight of less than 2500g for the variable
[WEIGHT] in the infant record (b_key) in the MOMBABY/CIHI dataset. Assess
on delivery date
Look at data carefully, as may need to troubleshoot errors in data entry
(kilograms vs. grams): a ‘0’ preceding the number (eg. 0900) implies that weight
reported in kilograms (eg. 90.0 kg), however many of these values may in fact
be reported in grams (eg. 900g). If value ≥ 0100, interpret as grams (eg. 100g). If
value <0100, interpret as kilograms (eg. 10.0 kg) and use 0001 as the lowest
possible birthweight allowed (eg. 0.1 kg or 100g).
2. Small for gestational age/Intrauterine growth restriction: Defined by codes in the
m_ikn, b_ikn, or b_key. Assess from delivery date to 12 weeks after the index
date
3. Premature birth: Defined as birth before 37 weeks of gestation using
[m_gestwks_del and b_gestwks_del] in mother and infant record in
MOMBABY dataset respectively where [b_stillbirth=F and m_stillbirth=F] or
the presence of a Prematurity/LowBirthweight code. Preferentially use infant
data source unless it is missing, in which case use mother data source. The
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•

absence) of AKI-D. Report the risk difference with 95% confidence
interval and the unadjusted relative risk with 95% confidence interval and
P-value.
Report the proportion of pregnancies in the AKI-D group that fulfilled the
maternal outcome definition of chronic dialysis dependence.
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